AXL receptor signaling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex and AXL inhibition is shown to increase the expression of p53 target genes and sensitize cells to cisplatin27. The gene discussed is MDM2; the disease is melanoma.